Exploring KSQ-4279, a First in Class USP1 Inhibitor for the Treatment of Tumors with Defects in DNA Damage Repair

Time: 12:30 pm
day: Day Two


  • Proprietary CRISPR screening platform identifies USP1 as a novel target that has a distinct, cancer-selective profile in comparison to other DDR targets that are often broadly cytotoxic
  • Delve into the potent, selective USP1 inhibitor, KSQ-4279, is active in patient-derived xenograft models with DDR defects both as a monotherapy and in combination with PARP inhibitors
  • Leveraging forward directions: KSQ-4279 Phase I trial is actively enrolling